Scholar Rock

About Scholar Rock

Scholar Rock is a biopharmaceutical company focused on the discovery, development, and delivery of innovative therapies to improve the lives of people with serious diseases. Their mission is to create new possibilities for patients through cutting-edge science.

Products & Services

Neuromuscular Therapies (Spinal Muscular Atrophy):Investigational therapies targeting spinal muscular atrophy under the neuromuscular focus area.

Cardiometabolic Disorders Therapies:Development of therapies for cardiometabolic disorders.

Immuno-Oncology Therapies (Cancer - Solid Tumors):Therapies targeting cancer, specifically solid tumors, in the immuno-oncology pipeline.

Fibrotic Diseases Therapies (Fibrosis):Investigational therapies aimed at treating fibrosis within fibrotic diseases.

Hematology Therapies (Anemia):Therapies focused on anemia under the hematology pipeline.

Specialties

Selective targeting of protein growth factors Neuromuscular disorders Cardiometabolic disorders Immuno-oncology Fibrotic diseases Hematology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering (Additional Shares) T: - FT: Public Offering (Additional Shares)	A: 45000000 MR: - FA: $45 million FAN: 45000000	D: 2024-10-16 FD: 2024-10-16	6 investors
2	RT: Public Offering T: - FT: Public Offering	A: 300000000 MR: - FA: $300 million FAN: 300000000	D: 2024-10-10 FD: 2024-10-10	6 investors
3	RT: Public Offering T: - FT: Public Offering	A: 275000000 MR: - FA: 275 million FAN: 275000000	D: 2024-10-07 FD: 2024-10-07	6 investors
4	RT: Public Offering T: - FT: Public Offering	A: 97800000 MR: - FA: $97.8 million FAN: 97800000	D: 2023-10-16 FD: 2023-10-16	4 investors
5	RT: Public Offering T: - FT: Public Offering	A: 85000000 MR: - FA: approximately $85.0 million FAN: 85000000	D: 2023-10-16 FD: 2023-10-16	4 investors
6	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 75000000 MR: - FA: $75.0 million FAN: 75000000	D: 2023-10-11 FD: 2023-10-11	4 investors

Public Offering (Additional Shares) Latest

2024-10-16

$45.0M

6 investors (Pro only)

Public Offering 2024-10-10

$300.0M

Public Offering 2024-10-07

$275.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Hallal

Chief Executive Officer & Chairman, Scholar Rock

S

Srini Akkaraju

Founder and Managing Partner, Samsara BioCapital

R

Richard Brudnick

Chief Business Officer, Prime Medicine

K

Kristina Burow

Managing Director, ARCH Venture Partners

J

Jeffrey Flier

Higginson Professor of Physiology and Medicine and Harvard University Distinguished Service Professor; Former Dean of Harvard Medical School

J

Jeffrey S. Flier

Higginson Professor of Physiology and Medicine and Harvard University Distinguished Service Professor; Former Dean of Harvard Medical School

View 20 more team members with Pro

Unlock Full Team Directory

Recent News

Scholar Rock Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised